Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov;125(11):1057-62.
doi: 10.1016/j.amjmed.2012.04.008. Epub 2012 Aug 17.

Hypertension and chronic kidney disease progression: why the suboptimal outcomes?

Affiliations
Review

Hypertension and chronic kidney disease progression: why the suboptimal outcomes?

Anil K Bidani et al. Am J Med. 2012 Nov.

Abstract

Current therapeutic interventions to retard the progression of chronic kidney disease have yielded disappointing outcomes despite adequate renin-angiotensin system blockade. The parameters to gauge the adequacy of blood pressure control need to be reassessed because clinic blood pressure constitutes a poor gauge of such control. The biologically relevant parameter for hypertensive target organ damage is total blood pressure burden, and reliance on isolated clinic blood pressure measurements per se does not accurately reflect the total blood pressure burden. This is particularly relevant to the population with chronic kidney disease in whom masked daytime or nocturnal hypertension and blood pressure lability are both widely prevalent and more difficult to control. Consequently, it is possible that the limited success currently being achieved in preventing or attenuating chronic kidney disease progression may be attributable in part to suboptimal 24-hour blood pressure control. Recent data and analyses also indicate that blood pressure variability, instability, episodic and nocturnal blood pressure elevations, and maximum systolic blood pressure may constitute additional strong predictors of the risk of target organ damage independently of mean systolic blood pressure. Accordingly, we suggest that future research should include the development of safe and effective strategies to achieve around-the-clock blood pressure control in addition to targeting mechanisms that reduce intrarenal blood pressure transmission or interrupt subsequent downstream pathways. Meanwhile, more aggressive use of patient education and home blood pressure monitoring with selection of longer-acting antihypertensive agents or nocturnal dosing should be considered to improve the current suboptimal results.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr Murray Epstein has served as a Consultant for Takeda Pharmaceuticals, Astra-Zeneca, Bayer & Co, and Merck. These consultations did not involve any drug cited in the article. Drs Anil K. Bidani and Karen A. Griffin: none.

Similar articles

  • Hypertension in 2016: Blood pressure goals, variability and SGLT2 blockade in CKD.
    Cohen DL, Townsend RR. Cohen DL, et al. Nat Rev Nephrol. 2017 Feb;13(2):75-76. doi: 10.1038/nrneph.2016.189. Epub 2016 Dec 28. Nat Rev Nephrol. 2017. PMID: 28029152 Review. No abstract available.
  • [New aspects of hypertension management in patients with chronic kidney disease].
    Vakilzadeh N, Phan O, Forni Ogna V, Burnier M, Wuerzner G. Vakilzadeh N, et al. Rev Med Suisse. 2014 Sep 10;10(441):1668-72. Rev Med Suisse. 2014. PMID: 25322626 Review. French.
  • Strict blood-pressure control and progression of renal failure in children.
    ESCAPE Trial Group; Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F. ESCAPE Trial Group, et al. N Engl J Med. 2009 Oct 22;361(17):1639-50. doi: 10.1056/NEJMoa0902066. N Engl J Med. 2009. PMID: 19846849 Clinical Trial.
  • Hypertension in Chronic Kidney Disease: Novel Insights.
    Duni A, Dounousi E, Pavlakou P, Eleftheriadis T, Liakopoulos V. Duni A, et al. Curr Hypertens Rev. 2020;16(1):45-54. doi: 10.2174/1573402115666190415153554. Curr Hypertens Rev. 2020. PMID: 30987570 Review.
  • Hypertension and Organ Damage in Women.
    Muiesan ML, Paini A, Aggiusti C, Bertacchini F, Rosei CA, Salvetti M. Muiesan ML, et al. High Blood Press Cardiovasc Prev. 2018 Sep;25(3):245-252. doi: 10.1007/s40292-018-0265-0. Epub 2018 Jun 26. High Blood Press Cardiovasc Prev. 2018. PMID: 29943358 Review.

Cited by

References

    1. Chobanian W, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252. - PubMed
    1. Kidney Disease Outcomes Quality Initiative (KDOQI) KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(Suppl 1):S1–S290. - PubMed
    1. Appel LJ, Wright JT, Jr, Green T, et al. for the African American Study of Kidney Disease. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008;168:832–839. - PMC - PubMed
    1. Appel LJ, Wright JT, Jr, Green T, et al. for the AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918–929. - PMC - PubMed
    1. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40:1175–1184. - PMC - PubMed

Publication types

MeSH terms

Substances